You are here

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

Last updated on December 7, 2019

FOR MORE INFORMATION
Study Location
Mobile, Alabama, 36604 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastroesophageal Reflux
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-5 year
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Ability to undergo endoscopy with required biopsy

- Ages 1 through 5 years

- Endoscopically confirmed GERD by positive endoscopic evidence of reflux related
esophagitis or positive histologic evidence of esophagitis consistent with GERD Other
inclusions apply.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History or presence of upper gastrointestinal anatomic or motor disorders

- Known current or active cow`s milk allergy

- Malignancy

- Other exclusions apply.

NCT00300755
Pfizer
Completed
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Gastroesophageal Reflux Disease
NCT02401035
All Genders
1+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
Official Title  ICMJE A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)
Brief SummaryTo evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Gastroesophageal Reflux
Intervention  ICMJE Drug: pantoprazole sodium enteric-coated spheroid
pediatric spheroids taken daily x 8 weeks
Study Arms  ICMJE
  • Active Comparator: 1
    Arm 1- Low Dose pantoprazole
    Intervention: Drug: pantoprazole sodium enteric-coated spheroid
  • Active Comparator: 2
    Arm 2- Medium Dose pantoprazole
    Intervention: Drug: pantoprazole sodium enteric-coated spheroid
  • Active Comparator: 3
    Arm 3- High Dose pantoprazole
    Intervention: Drug: pantoprazole sodium enteric-coated spheroid
Publications *Baker R, Tsou VM, Tung J, Baker SS, Li H, Wang W, Rath N, Maguire MK, Comer GM. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clin Pediatr (Phila). 2010 Sep;49(9):852-65. doi: 10.1177/0009922810369253. Epub 2010 Jun 3.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 14, 2010)
60
Original Enrollment  ICMJE
 (submitted: March 7, 2006)
65
Actual Study Completion Date  ICMJE April 2008
Actual Primary Completion DateApril 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Ability to undergo endoscopy with required biopsy
  • Ages 1 through 5 years
  • Endoscopically confirmed GERD by positive endoscopic evidence of reflux related esophagitis or positive histologic evidence of esophagitis consistent with GERD Other inclusions apply.

Exclusion Criteria:

  • History or presence of upper gastrointestinal anatomic or motor disorders
  • Known current or active cow`s milk allergy
  • Malignancy
  • Other exclusions apply.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Year to 5 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00300755
Other Study ID Numbers  ICMJE 3001B3-328
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyWyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Nycomed
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateApril 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now